These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31917036)

  • 1. Paclitaxel-coated peripheral artery devices are not associated with increased mortality.
    Kumins NH; King AH; Ambani RN; Thomas JP; Bose S; Shishehbor MH; Li J; Wong VL; Harth KC; Cho JS; Kashyap VS
    J Vasc Surg; 2020 Sep; 72(3):968-976. PubMed ID: 31917036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel-Coated Peripheral Arterial Devices are Associated with Reduced Mortality in Younger Patients.
    Kumins NH; King AH; Ambani RN; Thomas JP; Bose S; Wong VL; Harth KC; Cho JS; Colvard B; Kashyap VS
    Ann Vasc Surg; 2021 Jan; 70():70-78. PubMed ID: 32795647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
    Bertges DJ; Sedrakyan A; Sun T; Eslami MH; Schermerhorn M; Goodney PP; Beck AW; Cronenwett JL; Eldrup-Jorgensen J
    Circ Cardiovasc Interv; 2020 Feb; 13(2):e008528. PubMed ID: 32069110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
    Giannopoulos S; Kokkinidis DG; Jawaid O; Behan S; Hossain P; Alvandi B; Foley TR; Singh GD; Waldo SW; Armstrong EJ
    Cardiovasc Revasc Med; 2020 Jun; 21(6):771-778. PubMed ID: 31761634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Gebauer E; Cheung F; Lechner P; Nührenberg T; Zeller T
    JACC Cardiovasc Interv; 2020 Sep; 13(17):2052-2061. PubMed ID: 32593696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-coated peripheral arterial devices are associated with improved overall survival and limb salvage in patients with chronic limb-threatening ischemia.
    Kumins NH; King AH; Ambani RN; Cho JS; Harth KC; Wong VL; Colvard B; Bose S; Thomas JP; Kashyap VS
    J Vasc Surg; 2021 Nov; 74(5):1682-1688.e1. PubMed ID: 34090989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Katsanos K; Spiliopoulos S; Kitrou P; Krokidis M; Karnabatidis D
    J Am Heart Assoc; 2018 Dec; 7(24):e011245. PubMed ID: 30561254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and Mortality Following Peripheral Angioplasty: An Adjusted and Case Matched Multicentre Analysis.
    Saratzis A; Lea T; Yap T; Batchelder A; Thomson B; Saha P; Diamantopoulos A; Saratzis N; Davies R; Zayed H
    Eur J Vasc Endovasc Surg; 2020 Aug; 60(2):220-229. PubMed ID: 32370918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
    Katsuki T; Takahara M; Soga Y; Okamoto S; Iida O; Fujihara M; Kawasaki D; Ando K
    J Endovasc Ther; 2019 Oct; 26(5):593-599. PubMed ID: 31431154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
    JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A; Nerla R; Vadalà G; Castriota F; Grattoni C; Liso A; Russo P; Pantaleo P; Roscitano G; Cremonesi A
    JACC Cardiovasc Interv; 2017 Apr; 10(7):728-734. PubMed ID: 28385412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
    J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Dinh K; Gomes ML; Thomas SD; Paravastu SCV; Holden A; Schneider PA; Varcoe RL
    J Endovasc Ther; 2020 Apr; 27(2):175-185. PubMed ID: 32066315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.